Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
Verve Therapeutics (VERV) Stock Price & Analysis
368 Followers
VERV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.22 - $21.42
Previous Close$13.19
Volume647.69K
Average Volume (3M)1.10M
Market Cap
$1.04B
Enterprise Value$627.64M
Total Cash (Recent Filing)$485.23M
Total Debt (Recent Filing)$76.81M
Price to Earnings (P/E)-4.2
Beta2.58
Next Earnings
May 07, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding83,619,279
10 Day Avg. Volume1,151,137
30 Day Avg. Volume1,098,229
Standard Deviation0.26
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.32
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.09
Forecast
1Y Price Target
$40.00Price Target Upside201.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Verve Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $8.22 and its highest was $21.42 in the past 12 months.
What is Verve Therapeutics’s market cap?
Currently, no data Available
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 13 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Feb 27, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.064.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -$0.73.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 78,549,065 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went up 21.468%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Among the largest hedge funds holding Verve Therapeutics’s share is ARK Investment Management LLC. It holds Verve Therapeutics’s shares valued at 98M.
---
Verve Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (201.20% Upside)
$40.00 (201.20% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.45%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
10.82%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Months Forecast
Average Price Target
$40.00
▲(201.20% Upside)
Technical Analysis
Best Analysts Covering VERV
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-24.65%
assigned a buy rating 4 months ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -24.65% per trade.
---